FBIO Straddle Strategy

FBIO (Fortress Biotech, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies.

FBIO (Fortress Biotech, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $71.8M, a trailing P/E of 9.13, a beta of 1.16 versus the broader market, a 52-week range of 1.66-4.53, average daily share volume of 683K, a public-listing history dating back to 2011, approximately 101 full-time employees. These structural characteristics shape how FBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.16 places FBIO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 9.13 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.

What is a straddle on FBIO?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current FBIO snapshot

As of May 15, 2026, spot at $2.40, ATM IV 251.60%, IV rank 47.70%, expected move 72.13%. The straddle on FBIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this straddle structure on FBIO specifically: FBIO IV at 251.60% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 72.13% (roughly $1.73 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated FBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on FBIO should anchor to the underlying notional of $2.40 per share and to the trader's directional view on FBIO stock.

FBIO straddle setup

The FBIO straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With FBIO near $2.40, the first option leg uses a $2.40 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed FBIO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 FBIO shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$2.40	N/A
Buy 1	Put	$2.40	N/A

FBIO straddle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

FBIO straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on FBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use straddle on FBIO

Straddles on FBIO are pure-volatility plays that profit from large moves in either direction; traders typically buy FBIO straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

FBIO thesis for this straddle

The market-implied 1-standard-deviation range for FBIO extends from approximately $0.67 on the downside to $4.13 on the upside. A FBIO long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current FBIO IV rank near 47.70% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on FBIO should anchor more to the directional view and the expected-move geometry. As a Healthcare name, FBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to FBIO-specific events.

FBIO straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. FBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move FBIO alongside the broader basket even when FBIO-specific fundamentals are unchanged. Always rebuild the position from current FBIO chain quotes before placing a trade.

Frequently asked questions

What is a straddle on FBIO?: A straddle on FBIO is the straddle strategy applied to FBIO (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With FBIO stock trading near $2.40, the strikes shown on this page are snapped to the nearest listed FBIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are FBIO straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the FBIO straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 251.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a FBIO straddle?: The breakeven for the FBIO straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current FBIO market-implied 1-standard-deviation expected move is approximately 72.13%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on FBIO?: Straddles on FBIO are pure-volatility plays that profit from large moves in either direction; traders typically buy FBIO straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current FBIO implied volatility affect this straddle?: FBIO ATM IV is at 251.60% with IV rank near 47.70%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.